Abstract
Purpose
Patients affected by Cushing’s disease often have important comorbidities directly linked to hypercortisolism that might enhance the operative risk. We report the safety of transsphenoidal surgery in patients affected by Cushing’s disease as compared with patients with nonfunctioning pituitary adenoma.
Methods
We have retrospectively analyzed 142 patients with Cushing’s disease and 299 patients with nonfunctioning pituitary adenoma who underwent transsphenoidal surgery performed by a single experienced neurosurgeon between September 2007 and December 2014. For all of them, an intraoperative computerized anesthetic record for the automatic storage of data was available.
Results
The intraoperative vital parameters and the frequency of drugs administered during anesthesia were comparable between Cushing’s disease and nonfunctioning pituitary adenoma groups. The duration of surgery was similar between the two groups (41.2 ± 11.8 vs. 42.9 ± 15.6 min), while the duration of anesthesia was slightly shorter in Cushing’s disease patients (97.6 ± 18.1 min) than in nonfunctioning pituitary adenoma patients (101.6 ± 20.6 min, p = 0.04). The total perioperative mortality rate was 0.2% (0% in Cushing’s disease vs. 0.3% in nonfunctioning pituitary adenoma). Cushing’s disease patients had surgical and medical complication rates of 3.5% each, not different from those occurring in nonfunctioning pituitary adenoma. The postoperative incidence of diabetes insipidus (10.6%) and isolated hyponatremia (10.6%) in Cushing’s disease patients was significantly higher than in nonfunctioning pituitary adenoma patients (4.4 and 4.1%; p = 0.02 and p = 0.01, respectively).
Conclusions
In a large series of unselected and consecutive patients with Cushing’s disease, transsphenoidal surgery performed by one dedicated experienced neurosurgeon had a reasonably low risk of complications. In particular, despite the higher burden of comorbidities typically associated with hypercortisolism, medical complications are rare and no more frequent than in patients with nonfunctioning pituitary adenoma.
Similar content being viewed by others
References
C. Steffensen, A.M. Bak, K.Z. Rubeck, J.O. Jorgensen, Epidemiology of cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 1–5 (2010). doi:10.1159/000314297
M. Losa, P. Mortini, S. Dylgjeri, R. Barzaghi, A. Franzin, C. Mandelli, M. Giovanelli, Desmopressin stimulation test before and after pituitary surgery in patients with cushing’s disease. Clin. Endocrinol. 55(1), 61–68 (2001)
P. Mortini, M. Losa, R. Barzaghi, N. Boari, M. Giovanelli, Results of transsphenoidal surgery in a large series of patients with pituitary Adenoma. Neurosurgery 56(6), 1222–1233 (2005). doi:10.1227/01.neu.0000159647.64275.9d
B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A.R. Hermus, L.J. Hofland, A. Klibanski, A. Lacroix, J.R. Lindsay, J. Newell-Price, L.K. Nieman, S. Petersenn, N. Sonino, G.K. Stalla, B. Swearingen, M.L. Vance, J.A. Wass, M. Boscaro, Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin Endocrinol. Metab. 93(7), 2454–2462 (2008). doi:10.1210/jc.2007-2734
N.A. Tritos, B.M. Biller, B. Swearingen, Management of cushing disease. Nat. Rev. Endocrinol. 7(5), 279–289 (2011). doi:10.1038/nrendo.2011.12
R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The treatment of cushing’s disease. Endocr. Rev. 36(4), 385–486 (2015). doi:10.1210/er.2013-1048
R.R. Lonser, L. Nieman, E.H. Oldfield, Cushing’s disease: pathobiology, diagnosis, and management. J. Neurosurg. 1–14 (2016). 10.3171/2016.1.JNS152119
F.G. Barker 2nd, A. Klibanski, B. Swearingen, Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88(10), 4709–4719 (2003). doi:10.1210/jc.2003-030461
L.R. Barzaghi, M. Losa, M. Giovanelli, P. Mortini, Complications of transsphenoidal surgery in patients with pituitary adenoma: experience at a single centre. Acta. Neurochir. 149(9), 877–886 (2007). doi:10.1007/s00701-007-1244-8
I. Ciric, A. Ragin, C. Baumgartner, D. Pierce, Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40(2), 225–237 (1997)
A.N. Mamelak, Pro: endoscopic endonasal transsphenoidal pituitary surgery is superior to microscope-based transsphenoidal surgery. Endocrine 47(2), 409–414 (2014). doi:10.1007/s12020-014-0294-y
P. Mortini, Cons: endoscopic endonasal transsphenoidal pituitary surgery is not superior to microscopic transsphenoidal surgery for pituitary adenomas. Endocrine 47(2), 415–420 (2014). doi:10.1007/s12020-014-0365-0
A.L. Utz, B. Swearingen, B.M. Biller, Pituitary surgery and postoperative management in Cushing’s disease. Endocrinol. Metab. Clin. North. Am. 34(2), 459–478 (2005). doi:10.1016/j.ecl.2005.01.007. xi
R. Domi, Cushing’s surgery: role of the anesthesiologist. Indian. J. Endocrinol. Metab. 15(Suppl 4), S322–328 (2011). doi:10.4103/2230-8210.86975
S. Cannavo, E. Messina, A. Albani, F. Ferrau, V. Barresi, S. Priola, F. Esposito, F. Angileri, Clinical management of critically ill patients with cushing’s disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide. Endocrine 52(3), 481–487 (2016). doi:10.1007/s12020-015-0601-2
F. Castinetti, I. Morange, P. Jaquet, B. Conte-Devolx, T. Brue, Ketoconazole revisited: a preoperative or postoperative treatment in cushing’s disease. Eur. J. Endocrinol. 158(1), 91–99 (2008). doi:10.1530/EJE-07-0514
V.A. Preda, J. Sen, N. Karavitaki, A.B. Grossman, Etomidate in the management of hypercortisolaemia in cushing’s syndrome: a review. Eur. J. Endocrinol. 167(2), 137–143 (2012). doi:10.1530/EJE-12-0274
P. Kamenicky, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent cushing’s syndrome. J. Clin. Endocrinol. Metab. 96(9), 2796–2804 (2011). doi:10.1210/jc.2011-0536
K. McKeage, Pasireotide: a review of its use in cushing’s disease. Drugs 73(6), 563–574 (2013). doi:10.1007/s40265-013-0052-0
M.R. Gadelha, L. Vieira Neto, Efficacy of medical treatment in cushing’s disease: a systematic review. Clin. Endocrinol. 80(1), 1–12 (2014). doi:10.1111/cen.12345
O.F. van den Bosch, A.M. Stades, P.M. Zelissen, Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in cushing’s disease. Clin. Endocrinol. 80(2), 184–190 (2014). doi:10.1111/cen.12286
M. Losa, C.A. Donofrio, R. Barzaghi, P. Mortini, Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients’ characteristics. Eur. J. Endocrinol. 169(6), 735–742 (2013). doi:10.1530/EJE-13-0515
M. Gemma, C. Tommasino, S. Cozzi, S. Narcisi, P. Mortini, M. Losa, A. Soldarini, Remifentanil provides hemodynamic stability and faster awakening time in transsphenoidal surgery. Anesth. Analg. 94(1), 163–168 (2002)
P. Mortini, R. Barzaghi, M. Losa, N. Boari, M. Giovanelli, Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60(6), 993–1004 (2007). doi:10.1227/01.NEU.0000255459.14764.BA
M. Ammirati, L. Wei, I. Ciric, Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 84(8), 843–849 (2013). doi:10.1136/jnnp-2012-303194
T.J. Mampalam, J.B. Tyrrell, C.B. Wilson, Transsphenoidal microsurgery for cushing disease. A report of 216 cases. Ann. Intern. Med. 109(6), 487–493 (1988)
D. Bochicchio, M. Losa, M. Buchfelder, Factors influencing the immediate and late outcome of cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European cushing’s disease survey group. J. Clin. Endocrinol. Metab. 80(11), 3114–3120 (1995). doi:10.1210/jcem.80.11.7593411
U.J. Knappe, D.K. Ludecke, Persistent and recurrent hypercortisolism after transsphenoidal surgery for cushing’s disease. Acta. Neurochir. Suppl. 65, 31–34 (1996)
C. Invitti, F. Pecori Giraldi, M. de Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study group of the Italian society of endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 84(2), 440–448 (1999). doi:10.1210/jcem.84.2.5465
G.D. Hammer, J.B. Tyrrell, K.R. Lamborn, C.B. Applebury, E.T. Hannegan, S. Bell, R. Rahl, A. Lu, C.B. Wilson, Transsphenoidal microsurgery for cushing’s disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab. 89(12), 6348–6357 (2004). doi:10.1210/jc.2003-032180
C.G. Patil, D.M. Prevedello, S.P. Lad, M.L. Vance, M.O. Thorner, L. Katznelson, E.R. Laws Jr., Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J. Clin. Endocrinol. Metab. 93(2), 358–362 (2008). doi:10.1210/jc.2007-2013
B.M. Hofmann, M. Hlavac, R. Martinez, M. Buchfelder, O.A. Muller, R. Fahlbusch, Long-term results after microsurgery for cushing disease: experience with 426 primary operations over 35 years. J. Neurosurg. 108(1), 9–18 (2008). doi:10.3171/JNS/2008/108/01/0009
J. Jagannathan, R. Smith, H.L. DeVroom, A.O. Vortmeyer, C.A. Stratakis, L.K. Nieman, E.H. Oldfield, Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease. J. Neurosurg. 111(3), 531–539 (2009). doi:10.3171/2008.8.JNS08339
J.R. Lindsay, E.H. Oldfield, C.A. Stratakis, L.K. Nieman, The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing’s disease after transsphenoidal surgery. J. Clin. Endocrinol. Metab. 96(7), 2057–2064 (2011). doi:10.1210/jc.2011-0456
J.K. Lambert, L. Goldberg, S. Fayngold, J. Kostadinov, K.D. Post, E.B. Geer, Predictors of mortality and long-term outcomes in treated cushing’s disease: a study of 346 patients. J. Clin. Endocrinol. Metab. 98(3), 1022–1030 (2013). doi:10.1210/jc.2012-2893
W.F. Chandler, A.L. Barkan, T. Hollon, A. Sakharova, J. Sack, B. Brahma, D.E. Schteingart, Outcome of transsphenoidal surgery for cushing disease: a single-center experience over 32 years. Neurosurgery 78(2), 216–223 (2016). doi:10.1227/NEU.0000000000001011
R.A. Feelders, L.J. Hofland, W.W. de Herder, Medical treatment of cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92(Suppl 1), 111–115 (2010). doi:10.1159/000314292
P.L. Semple, E.R. Laws Jr., Complications in a contemporary series of patients who underwent transsphenoidal surgery for cushing’s disease. J. Neurosurg. 91(2), 175–179 (1999). doi:10.3171/jns.1999.91.2.0175
P.F. Svider, M.D. Raikundalia, M.J. Pines, S. Baredes, A.J. Folbe, J.K. Liu, J.A. Eloy, Inpatient complications after transsphenoidal surgery in cushing’s versus non-cushing’s disease patients. Ann. Otol. Rhinol. Laryngol. 125(1), 5–11 (2016). doi:10.1177/0003489415595424
R.A. Feelders, S.J. Pulgar, A. Kempel, A.M. Pereira, The burden of cushing’s disease: clinical and health-related quality of life aspects. Eur. J. Endocrinol. 167(3), 311–326 (2012). doi:10.1530/EJE-11-1095
R.N. Clayton, D. Raskauskiene, R.C. Reulen, P.W. Jones, Mortality and morbidity in cushing’s disease over 50 years in stoke-on-trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96(3), 632–642 (2011). doi:10.1210/jc.2010-1942
S.T. Sharma, L.K. Nieman, R.A. Feelders, Comorbidities in cushing’s disease. Pituitary 18(2), 188–194 (2015). doi:10.1007/s11102-015-0645-6
E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, E.S. Group, The European registry on cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165(3), 383–392 (2011). doi:10.1530/EJE-11-0272
L. Trementino, G. Arnaldi, G. Appolloni, V. Daidone, C. Scaroni, A. Casonato, M. Boscaro, Coagulopathy in cushing’s syndrome. Neuroendocrinology 92(Suppl 1), 55–59 (2010). doi:10.1159/000314349
M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in cushing’s syndrome. J. Clin. Endocrinol. Metab. 87(8), 3662–3666 (2002). doi:10.1210/jcem.87.8.8703
R. van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78(4), 481–488 (2013). doi:10.1111/cen.12094
R. Fahlbusch, M. Buchfelder, O.A. Muller, Transsphenoidal surgery for Cushing’s disease. J. R. Soc. Med. 79(5), 262–269 (1986)
I. Ciric, J.C. Zhao, H. Du, J.W. Findling, M.E. Molitch, R.E. Weiss, S. Refetoff, W.D. Kerr, J. Meyer, Transsphenoidal surgery for cushing disease: experience with 136 patients. Neurosurgery 70(1), 70–81 (2012). doi:10.1227/NEU.0b013e31822dda2c
T.R. Smith, M.M. Hulou, K.T. Huang, B. Nery, S.M. de Moura, D.J. Cote, E.R. Laws, Complications after transsphenoidal surgery for patients with cushing’s disease and silent corticotroph adenomas. Neurosurg. Focus. 38(2), E12 (2015). doi:10.3171/2014.10.FOCUS14705
D. Wilson, D.L. Jin, T. Wen, J.D. Carmichael, S. Cen, W.J. Mack, G. Zada, Demographic factors, outcomes, and patient access to transsphenoidal surgery for cushing’s disease: analysis of the nationwide inpatient sample from 2002 to 2010. Neurosurg. Focus. 38(2), E2 (2015). doi:10.3171/2014.11.FOCUS14694
B.R. Olson, D. Rubino, J. Gumowski, E.H. Oldfield, Isolated hyponatremia after transsphenoidal pituitary surgery. J. Clin. Endocrinol. Metab. 80(1), 85–91 (1995). doi:10.1210/jcem.80.1.7829644
Acknowledgements
We thank Dr. I. Snider for his contribution in the analysis of data obtained from the ICAR.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Donofrio, C.A., Losa, M., Gemma, M. et al. Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. Endocrine 58, 303–311 (2017). https://doi.org/10.1007/s12020-016-1214-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-016-1214-0